Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps

Current Opinion in Chemical Biology

Volumn 13, Issue 3, 2009, Pages 338-344

  Testa, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ADEFOVIR; ADEFOVIR DIPIVOXIL; CAPECITABINE; CLOPIDOGREL; FLUOROURACIL; ISOTAXEL; METRONIDAZOLE; OSELTAMIVIR; PACLITAXEL; PRADEFOVIR; PRASUGREL; PRODRUG; TIRAPAZAMINE; UNCLASSIFIED DRUG; ZANAMIVIR;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; NONHUMAN; PHARMACODYNAMICS; REVIEW;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; PRODRUGS;

EID: 67649849648     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.04.620     Document Type: Review

References (41)

1. Testa B, Krämer SD: The biochemistry of drug metabolism - an introduction. Part 5. Metabolism and bioactivity. Chem Biodivers 2009, 6: in press. An extensive (90 pages), structured and didactic review placing prodrugs in the broader context of metabolic activation and inactivation, toxification, and detoxification.
2. Raito J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Järvinen T., and Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7 (2008) 255-270. A well-organized, well-written, and information-rich review on the design of prodrugs and their clinical objectives.
3. Wermuth C.G. Designing prodrugs and bioprecursors. In: Wermuth C.G. (Ed). The Practice of Medicinal Chemistry. edn 3 (2008), Elsevier, Amsterdam 721-746
4. Testa B. Prodrugs. In: van de Waterbeemd H., and Testa B. (Eds). Drug Bioavailability - Estimation of Solubility, Permeability, Absorption and Bioavailability. edn 2 (2008), Wiley-VCH, Weinheim 559-570
5. Testa B: Prodrug objectives and design. In ADME-Tox Approaches. Edited by Testa B, van de Waterbeemd H. Volume 5 in Comprehensive Medicinal Chemistry II. Edited by Taylor JB, Triggle DJ. Oxford, UK: Elsevier; 2007:1009-1041.
6. In: Stella V.J., Borchardt R.T., Hageman M.J., Oliyai R., Maag H., and Tilley J.W. (Eds). Prodrugs: Challenges and Rewards. Parts 1 and 2 (2007), Springer, New York
7. Smith D.A. Do prodrugs deliver?. Curr Opin Drug Discov Dev 10 (2007) 550-559
8. Testa B. Prodrug research: futile or fertile?. Biochem Pharmacol 68 (2004) 2097-2106
9. Ettmayer P., Amidon G., Clement B., and Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem 47 (2004) 2393-2404
10. Mackman R.L., and Cihlar T. Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics. Annu Rep Med Chem 39 (2004) 305-321
11. Testa B., and Mayer J.M. Hydrolysis in Drug and Prodrug Metabolism - Chemistry, Biochemistry and Enzymology (2003), Wiley-VHCA, Zurich
12. Beaumont K., Webster R., Gardner I., and Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4 (2003) 461-485
13. Wang W., Jiang J., Ballard C.E., and Wang B. Prodrug approaches in the improved delivery of peptide drugs. Curr Pharm Des 5 (1999) 265-287
14. Lee H.J., You Z., Ko D.H., and McLean H.M. Recent advances in prodrugs and antedrugs. Curr Opin Drug Discov Dev 1 (1998) 235-244
15. Bradley D.A. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 19 (1996) 171-202
16. Albert A. Chemical aspects of selective toxicity. Nature 182 (1958) 421-422
17. Hayashi Y., Skwarczynski M., Hamada Y., Sohma Y., Kimura T., and Kiso Y. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: Design and synthesis of isotaxel. J Med Chem 47 (2004) 3782-3784
18. Skwarczynski M., Sohma Y., Noguchi M., Kimura M., Hayashi Y., Hamada Y., Kimura T., and Kiso Y. No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions. J Med Chem 48 (2005) 2655-2666
19. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12 (1995) 413-420
20. Abdel-Magid A.F., Maryanoff C.A., and Mehrman S.J. Synthesis of influenza neuraminidase inhibitors. Curr Opin Drug Disc Dev 4 (2001) 776-791
21. Reddy K.R., Matelich M.C., Ugarkar B.G., Gómez-Galeno J.E., DaRe J., Ollis K., Sun Z., Craigo W., Colby T.J., Fujitaki J.M., et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J Med Chem 51 (2008) 666-676
22. Rooseboom M., Commandeur J.N.M., and Vermeulen N.P.E. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56 (2004) 53-102
23. 19F NMR studies in animal models and human urine. Drug Metab Dispos 30 (2002) 1221-1229
24. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P., Pascal M., Herbert J.M., Maffrand J.P., and Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30 (2002) 1288-1295
25. Clarke T.A., and Waskell L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastin. Drug Metab Dispos 31 (2003) 53-59
26. Dansette P.M., Libraire J., Bertho G., and Mansuy D. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem Res Toxicol 22 (2009) 369-373. A remarkable research paper revealing new and significant details on the enzymatic mechanism of activation of antiaggregating prodrugs.
27. Farid N.A., Smith R.L., Gillespie T.A., Rash T.J., Blair P.E., Kurihara A., and Goldberg M.J. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35 (2007) 1096-1104
28. Williams E.T., Jones K.O., Ponsler G.D., Lowery S.M., Perkins E.J., Wrighton S.A., Ruterbories K.J., Kazui M., and Farid N.A. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 36 (2008) 1227-1232
29. Riley A.B., Tafreshi M.J., and Haber S.L. Prasugrel: a novel antiplatelet agent. Am J Health Syst Pharm 65 (2008) 1019-1028
30. Thompson A.M., Blaser A., Anderson R.F., Shinde S.S., Franzblau S.G., Ma Z., Denny W.A., and Palmer B.D. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem 52 (2009) 637-645. While nitro aromatic compounds are known since decades as antibacterial and antiparasitic bioprecursors, this study generates new hopes by applying the concept to the fight against tuberculosis.
31. Testa B., and Krämer S.D. The biochemistry of drug metabolism - an introduction. Part 2. Redox reactions and their enzymes. Chem Biodivers 4 (2007) 257-405
32. Anderson R.F., Shinde S.S., Hay M.P., Gamage S.A., and Denny W.A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 125 (2003) 748-756
33. Hay M.P., Pchalek K., Pruijn F.B., Hicks K.O., Siim B.G., Anderson R.F., Shinde S.S., Phillips V., Denny W.A., and Wilson W.R. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. J Med Chem 50 (2007) 6654-6664
34. Solano B., Junnotula V., Marin A., Villar R., Burguete A., Vicente E., Perez-Silanes S., Aldana I., Monge A., Dutta S., et al. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. J Med Chem 50 (2007) 5485-5492
35. Chen Y., and Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev 29 (2009) 29-64
36. Denny W.A. Hypoxia-activated anticancer drugs. Expert Opin Ther Patents 15 (2005) 635-646
37. Guise C.P., Wang A.T., Theil A., Bridewell D.J., Wilson W.R., and Patterson A.V. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH-cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 74 (2007) 810-820
38. Benz C.C., Atsriku C., Yau C., Britton D., Schilling B., Gibson B.W., Baldwin M.A., and Scott G.K. Novel pathways associated with quinone-induced stress in breast cancer cells. Drug Metab Rev 38 (2006) 601-613
39. Midgley I., Fitzpatrick K., Taylor L.M., Houchen T.L., Henderson S.J., Wright S.J., Cybulski Z.R., John B.A., McBurney A., Boykin D.W., et al. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rats and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride). Drug Metab Dispos 35 (2007) 955-967
40. Hall M.D., Mellor H.R., Callaghan R., and Hambley T.W. Basis for design and development of platinum(IV) anticancer complexes. J Med Chem 50 (2007) 3403-3411
41. 2] by aqueous extracts of cancer cells. J Med Chem 50 (2007) 5554-5556